Guang Zhou Ri Bao·2026-02-11 04:23Core Viewpoint - The announcement of the sixth batch of centralized procurement results in Zhejiang Province highlights the successful selection of Guangzhou Baiyunshan Xingqun Pharmaceutical Co., Ltd.'s Anshen Bnnao Liquid, reflecting the product's quality, clinical efficacy, and market reputation [1][4]. Group 1: Procurement Details - The sixth batch of centralized procurement includes a total of 45 varieties, consisting of 33 chemical drugs and 12 traditional Chinese medicines [3]. - The evaluation process follows a dual-track system of "technical review + price review," prioritizing core indicators such as clinical efficacy, reliability of quality, and safety [3]. - To ensure stable supply and demand for clinical medications, the evaluation includes an A/B group competitive mechanism, with A group having higher entry thresholds focusing on suppliers' capacity, processing techniques, and quality control [3]. Group 2: Company and Product Recognition - Baiyunshan Xingqun's Anshen Bnnao Liquid successfully emerged from the A group, indicating recognition of its medicinal efficacy and overall brand strength [4]. - The success in this procurement reflects the robust vitality of traditional Chinese medicine amid the expansion of centralized procurement, aiming to alleviate the public's concerns regarding high medication costs and accessibility [4]. - Xingqun Pharmaceutical is one of the first batch of "Chinese Time-honored Brands" and has been a pioneer in the modernization of traditional Chinese medicine [4]. Group 3: Future Outlook - The successful procurement is seen as a significant milestone in the company's development, with plans to continue focusing on innovation-driven growth and increasing investment in research and quality control [6]. - The company aims to provide stable and reliable products and services to medical institutions, contributing to the construction of a healthy China and the high-quality development of the traditional Chinese medicine industry [6].